Are clinical trial data shared sufficiently today?

Ben Goldacre, research fellow at the London School of Hygiene and Tropical Medicine, says we need all the evidence to make informed decisions about medicines.

The lack of progress on has been startling, he writes. Current suggest that around half of all trials for the treatments being used today have gone unpublished; and that trials with positive results are twice as likely to be published.

There is mandating greater transparency – such as the law requiring trial results to be posted on the website – but the published evidence now shows that this legislation has been largely ignored.

He also calls for trials from the past to be fully disclosed, since more than 80% of the medicines prescribed this year came onto the market more than a decade ago.

Claims that it's enough for regulators to see all the information on trials expose patients to "real and unnecessary risks," he adds, because problems with evidence are also identified by and working outside of regulatory bodies.

He says that Clinical Study Reports – long documents held by regulators and companies on the full methods and results of trials – should be shared publicly, with information about individual patients redacted where necessary. He explains that 1.6 million pages of this material have already been shared by the European Medicines Agency (EMA).

GlaxoSmithKline – the world's fourth largest drug company – has also committed to share all Clinical Study Reports going back to the foundation of the company, as part of the AllTrials campaign.

On the issue of patient privacy, he does not call for individual from trials to be published openly, but does point to several examples of "sensible and cautious sharing of [these] detailed " among professionals.

The problem of missing trials "is one of the greatest ethical and practical problems facing medicine today," writes Goldacre. "The AllTrials movement is driving the solution forwards: patients need industry to engage constructively with this widespread consensus, on the practical details – urgently – so that we can all move on."

But John Castellani, President of the Pharmaceutical Research and Manufacturers of America (PhRMA), says mandatory disclosure could affect patient privacy, stifle discovery, and allow competitors or unscrupulous actors to use the information.

"The biopharmaceutical industry is firmly committed to enhancing public health through responsible reporting and publication of clinical research and safety information," he writes.

He points out that information on clinical trials for potential new medicines is already required by US law to be posted on - and says the industry is also "engaged in a dynamic ongoing process to improve on all aspects of clinical trials."

However, he warns that threats to "will jeopardize patient willingness to participate in clinical trials, which would delay the availability of new therapies."

Mandatory public disclosure of clinical trial information, without appropriate scientific and clinical context, could also undermine patient trust and confidence in the safety and effectiveness of approved medicines, he writes.

He also raises concerns over disclosure of intellectual property, confidential commercial information, and proprietary scientific methods found in clinical , saying this "could stifle discovery and open the possibility of competitors or unscrupulous actors using the information for their own products in other markets or countries."

He outlines the huge investment and "considerable risk" involved in the search for new treatments, and concludes that "only a carefully balanced regulatory and competitive environment can foster the future investments in this research necessary to produce new treatments to benefit current and future patients."

More information:

add to favorites email to friend print save as pdf

Related Stories

Empowering children in clinical trials

Jun 20, 2013

There is evidence that over 50 percent of medicinal products developed for children have not been tested or authorised for use by this age group. The research project RESPECT ('Relating Expectations and Needs ...

Recommended for you

What are the chances that your dad isn't your dad?

Apr 16, 2014

How confident are you that the man you call dad is really your biological father? If you believe some of the most commonly-quoted figures, you could be forgiven for not being very confident at all. But how ...

New technology that is revealing the science of chewing

Apr 15, 2014

CSIRO's 3D mastication modelling, demonstrated for the first time in Melbourne today, is starting to provide researchers with new understanding of how to reduce salt, sugar and fat in food products, as well ...

After skin cancer, removable model replaces real ear

Apr 11, 2014

(HealthDay)—During his 10-year struggle with basal cell carcinoma, Henry Fiorentini emerged minus his right ear, and minus the hearing that goes with it. The good news: Today, the 56-year-old IT programmer ...

Italy scraps ban on donor-assisted reproduction

Apr 09, 2014

Italy's Constitutional Court on Wednesday struck down a Catholic Church-backed ban against assisted reproduction with sperm or egg donors that has forced thousands of sterile couples to seek help abroad.

User comments